Pharmaceutical Product Development (PPD) and Shin Nippon Biomedical Laboratories (SNBL) announced the formation of a joint venture in Japan to provide a range of clinical development services in that country, including Phase I–IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory, and FSP services.

The combination of SNBL’s clinical research division and PPD’s clinical development operations in Japan will be named PPD-SNBL, and it will have offices in Tokyo, Osaka, and Kagoshima with approximately 400 clinical development professionals. This combination brings together PPD’s global clinical trial expertise with SNBL’s nearly 20-year history of providing clinical development services for biopharmaceutical companies in Japan.

Under the terms of the agreement, PPD-SNBL will be majority owned by PPD. Ryoichi Nagata M.D., Ph.D., chairman and president of SNBL, will serve as the president of the JV. The parties have also entered into an agreement under which they will collaborate in a number of areas outside of the clinical development joint venture in Japan. This collaboration will involve SNBL’s early-stage businesses (including translational research out-licensing business), Phase I services in the United States for Japanese bridging studies, specialized neuroscience studies, vaccines studies and biologic studies, Phase I services in Japan, Japanese bioanalysis services, and site management services in Japan.